Hannah Constanty
Adult Health · Plattsburgh, NYNPI 1841806072
Payments from drug & device makers
Across 322 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Biohaven Pharmaceuticals, Inc.$694
- Lilly USA, LLC$416
- AstraZeneca$382
- GSK$368
- plus $1K from 24 others
What the payments were for
- Food & beverage$5,598100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 75 | $1,265 |
| Novo Nordisk | 64 | $1,098 |
| Biohaven Pharmaceuticals, Inc. | 29 | $694 |
| Lilly USA, LLC | 26 | $416 |
| AstraZeneca | 22 | $382 |
| GSK | 21 | $368 |
| Pfizer | 26 | $261 |
| Boehringer Ingelheim | 14 | $231 |
| Amgen | 5 | $108 |
| Abbott | 7 | $106 |
| Lundbeck LLC | 4 | $95 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Astellas Pharma US Inc | 3 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Gilead | 2 | $39 |
| Merck | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Novartis | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Bayer | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$5,598 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $92,503 |
| EliquisApixaban | 55 | $74,121 |
| MounjaroTirzepatide | 42 | $66,900 |
| RybelsusSemaglutide | 23 | $62,904 |
| JardianceEmpagliflozin | 31 | $46,160 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $38,010 |
| XareltoRivaroxaban | 22 | $36,966 |
| JanuviaSitagliptin Phosphate | 25 | $36,645 |
| FarxigaDapagliflozin Propanediol | 15 | $21,896 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $21,020 |
| TrintellixVortioxetine Hydrobromide | 11 | $14,054 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $12,331 |
| Novolog FlexpenInsulin Aspart | 19 | $8,899 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,883 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $5,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,098 | $155,40785 claims |
| PfizerEliquis | $261 | $74,12155 claims |
| Lilly USA, LLCMounjaro | $416 | $66,90042 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $231 | $65,37456 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $382 | $42,91635 claims |
| GSKTrelegy Ellipta | $368 | $38,01049 claims |
| Johnson & JohnsonXarelto | $23 | $36,96622 claims |
| MerckJanuvia | $33 | $36,64525 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $13 | $14,05411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.
Other adult health in Plattsburgh
- Jodi HamelPlattsburgh$17K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.